Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 12, 2009 Brian Orelli	Onyx Strikes Gold A nice pipeline pickup for this pharmaceutical company.
The Motley Fool February 24, 2010 Brian Orelli	A Profitable One-Drug Wonder! It's kind of impressive that Onyx Pharmaceuticals has made a profit two years in a row: $0.03 per share in 2008, and a much healthier $0.27 per share last year.
The Motley Fool August 8, 2007 Brian Orelli	Onyx Is Almost There Onyx Pharmaceutical narrowed losses for the quarter, and things should improve even more in the months to come, even as their bottom line is still being hampered by endless clinical trials.
The Motley Fool July 26, 2010 Brian Orelli	Up 20%! Guess That Hedge Wasn't Needed Onyx reports positive data for its recently acquired multiple myeloma drug.
The Motley Fool August 27, 2007 Brian Orelli	Onyx: Old News Is Good News Onyx set a 52-week high today, even though the good news wasn't all that new. After the recent dearth of FDA approvals, investors may be flocking to a drug that's nearly certain to get the agency's thumbs-up.
The Motley Fool November 20, 2007 Brian Orelli	Explaining Onyx Pharmaceuticals' Sell-Off The FDA approved Nexavar as a treatment for liver cancer, but the good news causes a sell-off of the stock.
The Motley Fool May 8, 2009 Brian Orelli	Growth in All the Wrong Places The potential of Onyx's tumor drug Nexavar will always be a major component in the company's value, but investors should watch the growth in current indications -- and where it's coming from -- in case the additional indications don't pan out.
The Motley Fool June 13, 2007 Brian Orelli	Evaluating a One-Trick Pony There is no doubt that investors should have bought Onyx Pharmaceuticals at its lows last December: The stock has tripled since then. The more important question is, what should you do now? Let's take a look at where Onyx is going.
The Motley Fool August 6, 2008 Brian Orelli	Onyx in the Black -- for Now Positive earnings, but losses may be ahead. Will Onyx be able to keep costs under control?
The Motley Fool May 14, 2007 Brian Lawler	Onyx Rocks The oncology-focused biotech announces first-quarter financial results. Investors, take note.
The Motley Fool November 8, 2007 Brian Orelli	Investors Prefer Black Onyx Sales of Onyx's only drug, Nexavar, exceeded $100 million in the third quarter, enough for Onyx to show a profit. Investors, take note.
The Motley Fool February 24, 2009 Brian Orelli	Back to the Red, but Not for Long After a few quarters in the black, Onyx Pharmaceuticals slips back into the red, reporting a loss of $30 million for the fourth quarter.
The Motley Fool December 5, 2006 Brian Lawler	Slight Setback for Onyx Onyx shares fell on disappointing news, but there are other opportunities for the one-drug wonder.
The Motley Fool February 13, 2007 Brian Lawler	Rock-Solid News From Onyx Results show that the drug Nexavar works in another type of cancer. But investors need to consider other issues when taking a closer look at this pharma.
The Motley Fool September 25, 2007 Brian Orelli	Onyx Moves Ahead Bayer and Onyx score a positive recommendation from an EU committee, moving one step closer to being able to market their cancer-fighting drug Nexavar in Europe.
The Motley Fool October 8, 2010 Luke Timmerman	Onyx Delays Cancer Drug Application As FDA Asks for More Data Shares fell about 7% in after-hours trading Thursday evening.
The Motley Fool April 28, 2009 Brian Orelli	Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off.
The Motley Fool December 12, 2011 Brian Orelli	FDA Irony: Less Data, Longer Review Poor Onyx Pharma.
The Motley Fool May 7, 2008 Brian Orelli	Black Onyx, but Not for Long Onyx posts a stellar quarter, but earnings for the pharmaceuticals company are headed in the other direction for the rest of the year.
The Motley Fool June 5, 2007 Billy Fisher	Onyx on Fire It is readily apparent that investors in the biopharma will sink or swim on the future results of Nexavar. The ASCO meeting marks an integral win for the company, but only time will tell whether the drug can push the company into the black.
The Motley Fool September 23, 2009 Brian Orelli	Nexavar, and Onyx, Nail It Investors have been anxiously awaiting this release of data from Onyx Pharmaceuticals' phase 2 trial testing Nexavar against breast cancer.
The Motley Fool June 28, 2007 Brian Orelli	Onyx's Hard at Work Onyx's future depends on getting Nexevar approved for new indications. The liver cancer expansion is a nice start, and it should bring Onyx into the black. Investors, take note.
The Motley Fool June 21, 2007 Brian Lawler	Onyx on the Clock The one-drug wonder's partner files a marketing application to expand the use of its lead drug. Investors, take note.
Chemistry World September 4, 2013 Sarah Houlton	Amgen snaps up Onyx in huge biotech deal The $10.4 billion deal gives Amgen access to the recently approved multiple myeloma drug carfilzomib (Kyprolis), plus several other partnered anticancer agents that are already on the market.
The Motley Fool June 4, 2010 Brian Orelli	This Cancer Drug's on a Roll Novartis' Afinitor scores another win.
The Motley Fool August 5, 2009 Brian Orelli	Potential Can't Buy Me Love It's sad when investors can't get excited about a company doubling its earnings per share and posting 19% growth in sales of its drug, but Onyx isn't going to get any love until it gets some positive clinical trial data.
The Motley Fool February 21, 2008 Brian Orelli	Onyx's Double Dose of Trouble Poor clinical trial data and a lack of profits hit the drugmaker hard. Investors, take note.
The Motley Fool May 18, 2009 Brian Orelli	Onyx Cries, "Et Tu, Brute?" The company is suing for the rights to a drug that marketing partner Bayer is developing.
Pharmaceutical Executive July 1, 2011	Precious Mettle Taking Onyx Pharmaceuticals to new heights: CEO Tony Coles talks about the midsize company's transition from adolescence to adulthood.
The Motley Fool November 7, 2008 Brian Orelli	Onyx -- Still Waiting Onyx licenses a pre-clinical drug from England's BTG International -- but it's got a new problem to worry about.
The Motley Fool April 3, 2009 Brian Orelli	Pfizer + Sutent = One Exciting Roller Coaster This time on the down slope, unfortunately.
The Motley Fool October 1, 2009 Brian Orelli	Geez, Lighten Up, Mr. Market! Investors dish out undue punishment to Onyx's stock.
The Motley Fool May 19, 2011 Brian Orelli	Pfizer Goes for a One-Two Blockbuster Knockout The pharma giant already has Sutent approved to treat kidney cancer, and now it's hoping to follow up that treatment with axitinib.
The Motley Fool March 31, 2009 Brian Orelli	A Good Start for a Potential Blockbuster Novartis' FDA approval for Afinitor is nice, but it needs another indication to be a blockbuster.
The Motley Fool January 7, 2009 Brian Orelli	A One-Hit Wonder Goes for No. 2 Onyx Pharmaceuticals announces its second license in the last few months.
The Motley Fool May 28, 2009 Brian Orelli	Make Money, Fight Disease: The ASCO Preview The big cancer meeting is upon us.
The Motley Fool December 6, 2011 Brian Orelli	Pfizer Faces Firing Line A panel of outside experts will help decide Inlyta's fate.
The Motley Fool April 13, 2011 Brian Orelli	Drug Duo Escapes Advisory Panel Unharmed Pfizer and Novartis are on their way to expanding their cancer drug indications.
The Motley Fool November 29, 2004 Brian Gorman	Glass Half Full for Bayer Bayer is battling drug recall demons, but the company's positives seem to outweigh its negatives. The German drug and chemical giant posted a net profit of $42 million, reversing a massive loss recorded in the same period last year.
The Motley Fool June 2, 2008 Brian Orelli	Valuing One-Drug Wonders With only one drug on the market, these pharmas lack positive earnings.
The Motley Fool June 15, 2010 Brian Orelli	Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug.
The Motley Fool July 7, 2010 Dave Mock	A Big Upgrade for Novartis This bullish call comes from more than just one analyst.
The Motley Fool October 30, 2007 Brian Orelli	Big Pharma's Takeover Wish List Which companies may be the next big pharma buyout candidates? Investors, take note.
The Motley Fool April 11, 2011 Brian Orelli	A Double Dose of Trouble for Big Pharma? Pfizer's Sutent and Novartis's Afinitor head in front of an FDA advisory panel.
The Motley Fool October 31, 2011 Brian Orelli	5 One-Drug Wonders Going for No. 2 Here are five drugmakers hoping not to become one-hit wonders: Vertex... Onyx... Momenta... Elan... Dendreon...
The Motley Fool June 25, 2008 Brian Orelli	An Even More Complicated Patent Settlement Barr and Bayer settle their dispute about Yasmin. That's as simple as it gets.
The Motley Fool April 14, 2011 Brian Orelli	Human Genome Sciences Will Be Profitable, Eventually With its first drug on the market -- nearly 20 years after the company was founded -- Human Genome Sciences should start to show meaningful revenue this year.
The Motley Fool March 22, 2005 Charly Travers	Do Good Drugs Guarantee Investment Success? By the time you know a drug is good, are you late to the party? Instead of trying to catch a train that has already zipped by, try investing in drug programs well in advance of phase 3 trials.
The Motley Fool March 3, 2005 Brian Gorman	Bayer Heals Itself The latest earnings report suggests things are looking up -- and drug development may soon yield more good news for investors.
The Motley Fool December 30, 2010 Brian Orelli	2011 Drugmaker M&A Targets What Big Pharma M&A deals will 2011 hold? Most likely, more small deals, and perhaps Sanofi will finally offer a reasonable price for Genzyme. Let's take a look at some of the companies that might be walking down the aisle next year.